Subgroup analysis by sex and baseline <scp>BMI</scp> in people with a <scp>BMI</scp> ≥27 kg/m <sup>2</sup> in the phase 2 trial of survodutide, a glucagon/ <scp>GLP</scp> ‐1 receptor dual agonist
In people with a BMI ≥27 kg/m<sup>2</sup>, survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI, and was tolerated at all doses tested.
Authors
- Anna Unseld
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Elena Startseva (ORCID: https://orcid.org/0000-0002-9363-7056)
- Kathryn Jean Lucas (ORCID: https://orcid.org/0000-0003-1197-1403)
- Anita M. Hennige (ORCID: https://orcid.org/0000-0002-5149-4966)
- Oren Steen (ORCID: https://orcid.org/0000-0001-8604-6891)
- Samina Ajaz Hussain (ORCID: https://orcid.org/0009-0002-4849-0363)
Institutions
- University College Dublin (IE)
- Boehringer Ingelheim (Germany) (DE)
- St. Vincent's University Hospital (IE)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1111/dom.16167
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18